China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun as its deputy general manager and chief strategy officer (CSO). Dr. Jiang will be tasked with overseeing clinical studies and driving business expansion. Moving forward, Sun Piaoyang, Zhang Lianshan, and Dr. Jiang Ningjun will form a strategic decision-making team at Hengrui, fully responsible for the firm’s future strategy and research and development (R&D) layout.
Dr. Jiang’s Background and Experience
Dr. Jiang is a graduate of Nanjing Medical University and holds a doctorate degree in Immunology from the University of British Columbia, Canada. He completed his post-doc work at the University of Washington Medical School. Dr. Jiang rose to the position of global vice-president and Asia-Pacific R&D head at Sanofi before leaving the French giant in 2016 to become chairman and CEO of CStone Pharmaceuticals (HKG: 2616). Under his leadership, CStone successfully debuted on the Hong Kong stock exchange in 2019 and achieved market approvals for four different cutting-edge products. Dr. Jiang decided to retire from his post in August 2022.
Impact on Hengrui’s Strategy and Development
The appointment of Dr. Jiang Ningjun as CSO is expected to significantly enhance Hengrui Medicine’s strategic capabilities. His extensive experience in R&D and business leadership will provide valuable insights and direction for Hengrui’s future growth. As the company continues to expand its pipeline and focus on innovative therapies, Dr. Jiang’s expertise will be instrumental in driving Hengrui’s mission to improve patient outcomes and address significant unmet medical needs.-Fineline Info & Tech
